Owkin vs Hippocratic AI

Detailed side-by-side comparison to help you choose the right tool

Owkin

Healthcare AI

Owkin is a full-stack AI biotech company using federated learning to train machine learning models on hospital data without centralizing patient records. Founded in 2016 and headquartered in Paris, Owkin reports major strategic biopharma partnerships and developed MSIntuit CRC, an FDA-cleared AI diagnostic for detecting microsatellite instability in colorectal cancer from standard pathology slides.

Was this helpful?

Starting Price

Custom

Hippocratic AI

🟢No Code

Healthcare AI

Healthcare AI agent platform handling 8M+ patient calls monthly with safety-focused LLM architecture for non-clinical patient interactions.

Was this helpful?

Starting Price

Custom

Feature Comparison

Scroll horizontally to compare details.

FeatureOwkinHippocratic AI
CategoryHealthcare AIHealthcare AI
Pricing Plans10 tiers6 tiers
Starting Price
Key Features
  • Federated learning via MOSAIC platform across 15+ academic medical centers worldwide
  • FDA-cleared MSIntuit CRC diagnostic for colorectal cancer microsatellite instability detection
  • Computational pathology using deep learning on whole-slide H&E-stained images

    Owkin - Pros & Cons

    Pros

    • Federated learning architecture via MOSAIC is designed to support training on real-world hospital data without centralizing patient records, potentially enabling access to diverse clinical datasets when appropriate agreements are in place
    • FDA 510(k)-cleared MSIntuit CRC diagnostic provides regulatory evidence for a specific colorectal cancer MSI screening use case, with performance and workflow claims requiring review of FDA materials and validation data
    • Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration provide public partnership signals for pharmaceutical use cases
    • Peer-reviewed publications in journals such as Nature Medicine and The Lancet Digital Health provide scientific credibility relative to less-published AI biotech peers
    • Founded in 2016 with substantial reported funding and a global office presence, which may give institutional clients additional confidence in long-term vendor viability
    • Multimodal approach combining pathology, genomics, spatial-omics and clinical data is intended to capture biological complexity beyond single-modality platforms

    Cons

    • Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
    • Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
    • Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
    • No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
    • Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
    • Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines

    Hippocratic AI - Pros & Cons

    Pros

    • Clinically validated at unprecedented scale — 725K+ test calls with 7,500+ licensed clinicians
    • Strictly non-diagnostic — avoids the regulatory minefield of AI-powered medical diagnosis
    • Consumption-based pricing ($0.20-$1.50/conversation) makes ROI straightforward to calculate
    • Agent App Store lets clinicians create custom agents without engineering resources
    • 8.7/10 patient satisfaction proves AI interactions can meet healthcare expectations

    Cons

    • Limited to non-clinical tasks — cannot assist with diagnosis, prescribing, or clinical decision-making
    • Enterprise pricing for full deployment requires sales engagement and contract negotiation
    • Proprietary architecture means no self-hosting or open-source flexibility
    • Integration with existing health system EHRs and workflows may require significant implementation effort
    • AI voice agents may frustrate patients who strongly prefer human interaction for healthcare conversations

    Not sure which to pick?

    🎯 Take our quiz →
    🦞

    New to AI tools?

    Read practical guides for choosing and using AI tools

    🔔

    Price Drop Alerts

    Get notified when AI tools lower their prices

    Tracking 2 tools

    We only email when prices actually change. No spam, ever.

    Get weekly AI agent tool insights

    Comparisons, new tool launches, and expert recommendations delivered to your inbox.

    No spam. Unsubscribe anytime.

    Ready to Choose?

    Read the full reviews to make an informed decision